Under the multi-country strategic partnership, the companies will commercialize CytoSorb for cardiac surgery applications. Financial terms of the deal have not been disclosed.
As per terms of the deal, Terumo will distribute CytoSorb cardiopulmonary bypass (CPB) procedure pack for intra-operative use during cardiac surgery in France, Sweden, Denmark, Norway, Finland, and Iceland.
The company received CE mark approval for CytoSorb to reduce the excessive production of inflammatory mediators in a range of conditions such as cardiac surgery.
In addition, the CytoSorbents is being used during and after cardiac surgery to remove inflammatory mediators such as cytokines and free hemoglobin that may lead to multiple organ failure.
Terumo perfusion and surgical devices division president Arik Anderson said: "Our collaboration with CytoSorbents enables us to offer this innovative, easy-to-use blood purification therapy to address our customers' most challenging cardiac cases.
"CytoSorb integrates with the heart-lung machine platform, giving surgical teams, for the first time, the ability to safely reduce dangerous inflammatory mediators in real-time as they are being generated during cardiac surgery."
CytoSorbents business development vice president Chris Cramer said: "The success of CytoSorb under this agreement provides the foundation for future expansion into strategically important markets, such as Japan, where Terumo is a leading medical device manufacturer."
Terumo Cardiovascular produces and markets medical devices for cardiac and vascular surgery applications.
